JP2005527585A - 末梢神経系の疾患の治療のためのピリミジンヌクレオチドの使用 - Google Patents
末梢神経系の疾患の治療のためのピリミジンヌクレオチドの使用 Download PDFInfo
- Publication number
- JP2005527585A JP2005527585A JP2003583436A JP2003583436A JP2005527585A JP 2005527585 A JP2005527585 A JP 2005527585A JP 2003583436 A JP2003583436 A JP 2003583436A JP 2003583436 A JP2003583436 A JP 2003583436A JP 2005527585 A JP2005527585 A JP 2005527585A
- Authority
- JP
- Japan
- Prior art keywords
- monophosphate
- uridine
- cytidine
- pharmaceutical composition
- polyneuropathy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
軸索突起は病変の位置で変性する。断片形成が起こる。被覆組織のミエリンもこのプロセスに含まれ、そして約8日以内に分解する。
離断された神経領域の近位および遠位残根で、シュワン細胞が分裂する。若い軸索突起が出芽し、そしてタンパク質、脂質およびRNAを蓄積する。Bungnerバンドは、離断したフィラメント片間の接続を再構築しようと試みる。若い軸索突起は、この先導に沿って移動する。
新しい神経フィラメントが、髄鞘形成のため厚く発達する。新しい細胞構造が構築される。
プラセボのみを投与された患者と比較して、UMP患者の場合に、最初の注射後の最初の24時間以内には、既に、痛みの明らかな減弱を観察し得る(表1を参照のこと)。
Claims (9)
- 末梢神経系の疾患の治療および/または神経再生の刺激のためのウリジン5’-一リン酸またはシチジン5’-一リン酸の使用。
- 前記ウリジン5’-一リン酸が関係することを特徴とする、請求項1に記載の使用。
- 前記末梢神経系の疾患が、多発性神経障害、神経炎、および/またはミオパシーに関係する、請求項1または2に記載の使用。
- 前記多発性神経障害、神経炎、およびミオパシーが、脊柱の変性疾患、糖尿病性の多発性神経障害、アルコール乱用後の多発性神経障害、その他の中毒性の多発性神経障害、顔面神経不全麻痺、顔面神経痛、多発性硬化症、根神経炎、頸部症候群、肩腕症候群、坐骨神経痛、腰痛、肋間神経痛、三叉神経痛、および/または帯状ヘルペスに関係する、請求項3に記載の使用。
- 前記ウリジン5’-一リン酸またはシチジン5’-一リン酸が、1〜100mg、好ましくは5〜50mg、および最も好ましくは7〜40mgの1日投与量で投与される、請求項1から4のいずれかに記載の使用。
- 末梢神経系の疾患の治療および/または神経再生の刺激のための薬学的組成物の製造におけるウリジン5’-一リン酸またはシチジン5’-一リン酸の使用。
- 薬学的に活性な成分としてウリジン5’-一リン酸またはシチジン5’-一リン酸を、必要に応じて生理的に受容可能なキャリア、補助剤、および/または希釈剤とともに含む、薬学的組成物。
- 前記単回の薬学的組成物が、1〜100mg、好ましくは5〜50mg、および最も好ましくは7〜40mgの濃度でウリジン5’-一リン酸またはシチジン5’-一リン酸を含有する、請求項7に記載の薬学的組成物。
- 前記薬学的組成物が経口適用または注射に適する、請求項7または8に記載の薬学的組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10215753.7 | 2002-04-10 | ||
DE10215753A DE10215753A1 (de) | 2002-04-10 | 2002-04-10 | Verwendung von Pyrimidinnukleotiden zur Behandlung von Schädigungen des peripheren Nervensystems |
PCT/DE2003/001203 WO2003086417A1 (de) | 2002-04-10 | 2003-04-10 | Verwendung von pyrimidinnukleotiden zur behandlung von schädigungen des peripheren nervensystems |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010080954A Division JP2010155861A (ja) | 2002-04-10 | 2010-03-31 | 末梢神経系の疾患の治療のためのピリミジンヌクレオチドの使用 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2005527585A true JP2005527585A (ja) | 2005-09-15 |
JP2005527585A5 JP2005527585A5 (ja) | 2006-01-05 |
JP5204943B2 JP5204943B2 (ja) | 2013-06-05 |
Family
ID=28684902
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003583436A Expired - Fee Related JP5204943B2 (ja) | 2002-04-10 | 2003-04-10 | 末梢神経系の疾患の治療のためのピリミジンヌクレオチドの使用 |
JP2010080954A Pending JP2010155861A (ja) | 2002-04-10 | 2010-03-31 | 末梢神経系の疾患の治療のためのピリミジンヌクレオチドの使用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010080954A Pending JP2010155861A (ja) | 2002-04-10 | 2010-03-31 | 末梢神経系の疾患の治療のためのピリミジンヌクレオチドの使用 |
Country Status (15)
Country | Link |
---|---|
US (1) | US7807655B2 (ja) |
EP (1) | EP1492546B1 (ja) |
JP (2) | JP5204943B2 (ja) |
KR (1) | KR20040105861A (ja) |
CN (1) | CN1646139B (ja) |
AT (1) | ATE361079T1 (ja) |
AU (1) | AU2003233749A1 (ja) |
BR (1) | BR0309129A (ja) |
CA (1) | CA2481263C (ja) |
DE (3) | DE10215753A1 (ja) |
DK (1) | DK1492546T3 (ja) |
ES (1) | ES2286433T3 (ja) |
MX (1) | MXPA04009802A (ja) |
PT (1) | PT1492546E (ja) |
WO (1) | WO2003086417A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10215753A1 (de) | 2002-04-10 | 2003-10-30 | Trommsdorff Arzneimittel | Verwendung von Pyrimidinnukleotiden zur Behandlung von Schädigungen des peripheren Nervensystems |
JP4482493B2 (ja) * | 2005-06-29 | 2010-06-16 | 明治飼糧株式会社 | ロタウイルス感染・増殖抑制剤 |
EP3965744A1 (en) * | 2019-05-06 | 2022-03-16 | Ferrer Internacional, S.A. | Multilayer pharmaceutical or nutraceutical solid dosage forms comprising pyrimidine and/or purine derivatives and b vitamins, preparation and uses thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05252899A (ja) * | 1992-03-03 | 1993-10-05 | Snow Brand Milk Prod Co Ltd | 生体組織内ω3系脂肪酸増加剤及びそれを含む栄養組成物 |
JP2001233776A (ja) * | 2000-02-25 | 2001-08-28 | Yamasa Shoyu Co Ltd | 学習・記憶能低下改善剤およびその用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4204108C2 (de) * | 1992-02-12 | 1998-09-24 | Kragler Peter | Arzneimittel zur Behandlung und/oder Prophylaxe von Störungen des Folat-Stoffwechsels |
DE10215753A1 (de) | 2002-04-10 | 2003-10-30 | Trommsdorff Arzneimittel | Verwendung von Pyrimidinnukleotiden zur Behandlung von Schädigungen des peripheren Nervensystems |
-
2002
- 2002-04-10 DE DE10215753A patent/DE10215753A1/de not_active Withdrawn
-
2003
- 2003-04-10 WO PCT/DE2003/001203 patent/WO2003086417A1/de active IP Right Grant
- 2003-04-10 JP JP2003583436A patent/JP5204943B2/ja not_active Expired - Fee Related
- 2003-04-10 AT AT03727197T patent/ATE361079T1/de active
- 2003-04-10 KR KR10-2004-7016184A patent/KR20040105861A/ko active Search and Examination
- 2003-04-10 EP EP03727197A patent/EP1492546B1/de not_active Expired - Lifetime
- 2003-04-10 DK DK03727197T patent/DK1492546T3/da active
- 2003-04-10 DE DE50307173T patent/DE50307173D1/de not_active Expired - Lifetime
- 2003-04-10 AU AU2003233749A patent/AU2003233749A1/en not_active Abandoned
- 2003-04-10 CN CN038081067A patent/CN1646139B/zh not_active Expired - Fee Related
- 2003-04-10 CA CA002481263A patent/CA2481263C/en not_active Expired - Fee Related
- 2003-04-10 ES ES03727197T patent/ES2286433T3/es not_active Expired - Lifetime
- 2003-04-10 BR BR0309129-5A patent/BR0309129A/pt not_active Application Discontinuation
- 2003-04-10 PT PT03727197T patent/PT1492546E/pt unknown
- 2003-04-10 MX MXPA04009802A patent/MXPA04009802A/es active IP Right Grant
- 2003-04-10 US US10/511,026 patent/US7807655B2/en not_active Expired - Fee Related
- 2003-04-10 DE DE10391491T patent/DE10391491D2/de not_active Expired - Fee Related
-
2010
- 2010-03-31 JP JP2010080954A patent/JP2010155861A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05252899A (ja) * | 1992-03-03 | 1993-10-05 | Snow Brand Milk Prod Co Ltd | 生体組織内ω3系脂肪酸増加剤及びそれを含む栄養組成物 |
JP2001233776A (ja) * | 2000-02-25 | 2001-08-28 | Yamasa Shoyu Co Ltd | 学習・記憶能低下改善剤およびその用途 |
Also Published As
Publication number | Publication date |
---|---|
DE10391491D2 (de) | 2005-02-17 |
WO2003086417A1 (de) | 2003-10-23 |
CA2481263C (en) | 2009-09-29 |
CN1646139A (zh) | 2005-07-27 |
CA2481263A1 (en) | 2003-10-23 |
WO2003086417B1 (de) | 2004-02-12 |
DK1492546T3 (da) | 2007-09-10 |
JP5204943B2 (ja) | 2013-06-05 |
ES2286433T3 (es) | 2007-12-01 |
AU2003233749A1 (en) | 2003-10-27 |
BR0309129A (pt) | 2005-02-01 |
DE10215753A1 (de) | 2003-10-30 |
CN1646139B (zh) | 2011-09-28 |
KR20040105861A (ko) | 2004-12-16 |
ATE361079T1 (de) | 2007-05-15 |
US20050222078A1 (en) | 2005-10-06 |
JP2010155861A (ja) | 2010-07-15 |
DE50307173D1 (de) | 2007-06-14 |
PT1492546E (pt) | 2007-08-13 |
US7807655B2 (en) | 2010-10-05 |
MXPA04009802A (es) | 2004-12-13 |
EP1492546B1 (de) | 2007-05-02 |
EP1492546A1 (de) | 2005-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2002518983A (ja) | 迷走神経トーンの調整方法 | |
AU2018266106B2 (en) | Pharmaceutical compositions and methods of treating cardiovascular diseases | |
EA006598B1 (ru) | Композиция, содержащая трамадол и противосудорожное лекарственное средство | |
US20130028958A1 (en) | Beta-carbolines for use in the treatment of hearing loss and vertigo | |
DE69821498T2 (de) | Verwendung von amifostin | |
JP2010155861A (ja) | 末梢神経系の疾患の治療のためのピリミジンヌクレオチドの使用 | |
CN110585226B (zh) | 金线莲苷在制备改善认知功能障碍的药物中的用途 | |
CN113234141B (zh) | 一种多肽的新用途 | |
CN115942934A (zh) | 卟啉症的预防或治疗剂 | |
JP3725172B2 (ja) | ウリジンからなる神経変性疾患の処置に活性な治療剤 | |
EP1448189A2 (en) | Use of bisindolmaleimide and gemcitabine for the treatment of cancer | |
ES2483940T3 (es) | Un nuevo régimen de dosificación para compuestos moduladores del canal iónico para el tratamiento de la fibrilación auricular aguda en un ser humano | |
US6916845B2 (en) | Method for prevention and treatment of male and female sexual dysfunction | |
US20170095497A1 (en) | Transient inhibition of adenosine kinase as an anti-epileptogenesis treatment | |
CN101260063A (zh) | γ-氨基丁酸衍生物及其制备方法 | |
JP2005527585A5 (ja) | ||
US6413976B1 (en) | Compositions and method for decreasing neuropathic pain | |
TWI331993B (en) | Aminocyclohexyl ether compounds and uses thereof | |
AU618325B2 (en) | Improvements in or relating to organic compounds | |
CN117180292A (zh) | 红景天苷或红景天提取物用于制备治疗心脏传导阻滞药物 | |
CN100379411C (zh) | 二甲基苯氧基烷胺用于制备抗耳鸣药物的用途 | |
CN117180291A (zh) | 红景天苷或红景天提取物用于制备电压门控钠通道激动剂 | |
Blackwell | Antidepressant drugs | |
CN112402408A (zh) | 盐酸丙美卡因及其衍生化合物在制备预防和/或治疗癫痫药物中的应用 | |
UA122750C2 (uk) | Фармацевтична композиція на основі пуринових нуклеотидів з посиленим впливом на аденозинові рецептори |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051026 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051026 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090630 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090930 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20091201 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20101201 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121203 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20121203 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130218 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5204943 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160222 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |